Towards an Effective Rapprochement Between Artificial Intelligence and Medical and Pharmaceutical Research

Qeis Kamran; Berit Schumann

doi:10.31031/MADD.2022.03.000570

Towards an Effective Rapprochement Between Artificial Intelligence and Medical and Pharmaceutical Research

Qeis Kamran, Berit Schumann

Product—Market Relations

Research output: Contribution to journal › Article › Academic › peer-review

141 Downloads (Pure)

Abstract

The contemporary era of technological advancement enhances pharmaceutical and medical research to investigate the benefits of AI in drug design and development. The complexity of its globalized nature attaches risks and yet unknown challenges for businesses but can simultaneously provide many solid opportunities for urgent drug trials and designs as well as public health issues as experienced during the current Covid-19 pandemic. This review demonstrates potential benefits from the evolution of market dimensions for pharmaceutical companies, using the case of BioNTech during the Covid19-pandemic, accelerating drug design and distribution by enhancing a unique design proposition and design dominant logic. A model will be introduced which allows companies to revolutionize their ways from unique selling propositions to unique meaning and unique design propositions.

Original language	English
Pages (from-to)	1-4
Number of pages	4
Journal	Modern Approaches in Drug Designing
Volume	3
Issue number	4
DOIs	https://doi.org/10.31031/MADD.2022.03.000570
Publication status	Published - 26 Apr 2022

Keywords

Artificial intelligence; Machine learning; Deep learning; Complexity; Drug discovery; Design dominant logic; Creating shared value

Access to Document

10.31031/MADD.2022.03.000570Licence: CC BY

MADD.000570Final published version, 370 KBLicence: CC BY

Cite this

@article{ad88201f5759487a946b5d7b39304880,

title = "Towards an Effective Rapprochement Between Artificial Intelligence and Medical and Pharmaceutical Research",

abstract = "The contemporary era of technological advancement enhances pharmaceutical and medical research to investigate the benefits of AI in drug design and development. The complexity of its globalized nature attaches risks and yet unknown challenges for businesses but can simultaneously provide many solid opportunities for urgent drug trials and designs as well as public health issues as experienced during the current Covid-19 pandemic. This review demonstrates potential benefits from the evolution of market dimensions for pharmaceutical companies, using the case of BioNTech during the Covid19-pandemic, accelerating drug design and distribution by enhancing a unique design proposition and design dominant logic. A model will be introduced which allows companies to revolutionize their ways from unique selling propositions to unique meaning and unique design propositions.",

keywords = "Artificial intelligence; Machine learning; Deep learning; Complexity; Drug discovery; Design dominant logic; Creating shared value",

author = "Qeis Kamran and Berit Schumann",

note = "Qeis Kamran* and Berit Schumann. Towards an Effective Rapprochement Between Artificial Intelligence and Medical and Pharmaceutical Research. Mod Appro Drug Des. 3(4). MADD. 000570. 2022. DOI: 10.31031/MADD.2022.03.000570",

year = "2022",

month = apr,

day = "26",

doi = "10.31031/MADD.2022.03.000570",

language = "English",

volume = "3",

pages = "1--4",

journal = "Modern Approaches in Drug Designing",

issn = "2576-9170",

publisher = "Crimson Publishers LLC",

number = "4",

}

TY - JOUR

T1 - Towards an Effective Rapprochement Between Artificial Intelligence and Medical and Pharmaceutical Research

AU - Kamran, Qeis

AU - Schumann, Berit

N1 - Qeis Kamran* and Berit Schumann. Towards an Effective Rapprochement Between Artificial Intelligence and Medical and Pharmaceutical Research. Mod Appro Drug Des. 3(4). MADD. 000570. 2022. DOI: 10.31031/MADD.2022.03.000570

PY - 2022/4/26

Y1 - 2022/4/26

N2 - The contemporary era of technological advancement enhances pharmaceutical and medical research to investigate the benefits of AI in drug design and development. The complexity of its globalized nature attaches risks and yet unknown challenges for businesses but can simultaneously provide many solid opportunities for urgent drug trials and designs as well as public health issues as experienced during the current Covid-19 pandemic. This review demonstrates potential benefits from the evolution of market dimensions for pharmaceutical companies, using the case of BioNTech during the Covid19-pandemic, accelerating drug design and distribution by enhancing a unique design proposition and design dominant logic. A model will be introduced which allows companies to revolutionize their ways from unique selling propositions to unique meaning and unique design propositions.

AB - The contemporary era of technological advancement enhances pharmaceutical and medical research to investigate the benefits of AI in drug design and development. The complexity of its globalized nature attaches risks and yet unknown challenges for businesses but can simultaneously provide many solid opportunities for urgent drug trials and designs as well as public health issues as experienced during the current Covid-19 pandemic. This review demonstrates potential benefits from the evolution of market dimensions for pharmaceutical companies, using the case of BioNTech during the Covid19-pandemic, accelerating drug design and distribution by enhancing a unique design proposition and design dominant logic. A model will be introduced which allows companies to revolutionize their ways from unique selling propositions to unique meaning and unique design propositions.

KW - Artificial intelligence; Machine learning; Deep learning; Complexity; Drug discovery; Design dominant logic; Creating shared value

U2 - 10.31031/MADD.2022.03.000570

DO - 10.31031/MADD.2022.03.000570

M3 - Article

SN - 2576-9170

VL - 3

SP - 1

EP - 4

JO - Modern Approaches in Drug Designing

JF - Modern Approaches in Drug Designing

IS - 4

ER -

Towards an Effective Rapprochement Between Artificial Intelligence and Medical and Pharmaceutical Research

Abstract

Keywords

Access to Document

Fingerprint

Cite this